Lv5
960 积分 2023-06-12 加入
NNMT enhances invasive and migratory capacity of keloid fibroblasts and M2 macrophage polarization
2天前
已完结
Covalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2
1个月前
已完结
Tumor-Associated Carbohydrate Antigens (TACA) as Novel Targets for Anticancer Therapy
1个月前
已完结
Pharmacology and pharmacokinetics of tazemetostat
1个月前
已完结
Connecting genotype and phenotype in minor spliceosome diseases
1个月前
已完结
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
2个月前
已完结
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
2个月前
已完结
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
2个月前
已完结
Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study
2个月前
已完结
Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study
2个月前
已完结
皖公网安备34019202002308
